glp-1 antagonist drugs Costs Explained: Managing Coverage Challenges GLP-1 receptor agonists – How
Description
In clinical trials, it led to a weight reduction of up to 16.2%
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic drugs that improve glycemic control and many other atherosclerosis-related parameters in patients with type 2 diabetes (T2D)
Guidelines currently recommend organ-specific management of obesity-related complications
Results At 1 year, patients achieved significant weight loss with a median total weight loss (%TWL) of 25.5% and a median excess weight loss (%EWL) of 66.3% compared to 16.6% and 40.8%, respectively, at treatment initiation with BMI reduction of 3.7 kg/m2
Connect with certified providers on Meto for personalized support and results
Personalized medical support can prevent or mitigate these symptoms, improving adherence and the overall success of the therapy
